Day: September 19, 2024

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

Written by Customer Service on . Posted in Public Companies.

ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced risk of relapse and rapid onset of action VYVGART Hytrulo is first and only neonatal Fc receptor (FcRn) blocker FDA-approved to treat CIDP September 19, 2024 – 7:00 am CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced publication in The Lancet Neurology of the pivotal ADHERE Study, the largest clinical trial to date in chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP is a rare, debilitating, often progressive, immune-mediated neuromuscular disorder of the peripheral nervous system....

Continue reading

Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses

Written by Customer Service on . Posted in Public Companies.

Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household members This is the first time that any antiviral used in the treatment of a respiratory viral illness has demonstrated a transmission reduction benefit in a global phase III study Reducing the spread of infection in the household could help limit transmission within communities and societies, easing the burden of both seasonal and pandemic influenza on healthcare systems Basel, 19 September – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results of the phase III CENTERSTONE study of Xofluza® (baloxavir marboxil), an antiviral, showing a reduction in the transmission of influenza viruses. The study met its primary endpoint, demonstrating that a single, oral dose of Xofluza taken...

Continue reading

Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit

Written by Customer Service on . Posted in Public Companies.

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 19, 2024 – Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its provisional half-year and second quarter net results have increased significantly in 2024 compared to 2023 and first quarter 2024 results primarily due to the sale of part of its business to Neurosterix Pharma Sàrl on April 2, 2024. The provisional result amount to a net gain of CHF 9.8 million for the six-month period ended June 30, 2024 compared to a net loss of CHF 5.1 million for the six-month period ended June 30, 2023. The increase of CHF 14.9 million is primarily due to the gross proceeds of CHF 5.0 million received in cash from...

Continue reading

Correction: Tonner Drones Convenes GM and Expands Strategy

Written by Customer Service on . Posted in Public Companies.

Tonner Drones Convenes GM and Expands Strategy Cannes, 18 September 2024 18:00, Tonner Drones (the “Company”) is pleased to announce that it is convening a shareholders’ general meeting to be held on October 21th (the “GM”) so that shareholders can vote on several important resolutions including the mandate to expand its strategy. Mandate Strategy During the GM, shareholders will be asked to vote on a mandate to implement a new strategy and amend the articles of association accordingly. The Company has successfully completed a restructuring and refinancing process by, among other items, settling various financing contracts and terminating all equity-lines. The Company’s new management is convinced that it can also help other listed companies to escape similar stifling financing structures. The Company is in the position to advise the...

Continue reading

Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding

Written by Customer Service on . Posted in Public Companies.

Initial funding of USD 29 million to support development of Basilea’s clinical stage first-in-class antifungals, fosmanogepix and BAL2062 Multi-year Other Transaction Agreement (OTA) allows for potential funding of up to approximately USD 268 million to develop antifungal and antibacterial assets Increasing FY 2024 financial guidance on total revenue, operating result and net profit Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, September 19, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of...

Continue reading

Central Iron Ore Limited: Drilling Results Finalised

Written by Customer Service on . Posted in Public Companies.

VANCOUVER, British Columbia, Sept. 18, 2024 (GLOBE NEWSWIRE) — Central Iron Ore Limited (CIO – TSX.V) (“CIO” or “the Company”) is pleased to announce this Drilling Update. Central Iron Ore is pleased to announce that the results for the 2024 Phase 1 RC drilling campaign have been finalised. Figure 1. The sun sets after the first day’s drilling of the 2024 Phase 1 RC campaign at British King (M37/30) Highlights: Assay results for the 75-hole, 5 911-meter 2024 Phase 1 RC program has been received and processed. Multiple significant intercepts exceeding has been intercepted across the target area (Table 1) some notable intercepts include; 24BKRC_004: 5m @ 20.52g/t from 110 meters 24BKRC_007: 3m @ 28.26g/t from 96 meters 24BKRC_010: 2m @ 24.02g/t from 75 meters 24BKRC_015: 3m @ 35.61g/t from 58 meters 24BKRC_028: 7m @ 8.53g/t...

Continue reading

Bel Announces Agreement to Acquire Enercon Technologies

Written by Customer Service on . Posted in Mergers And Acquisitions.

Significantly expands Bel’s presence in the higher-margin Aerospace & Defense markets, enhancing our financial profile, expanding our product portfolio and diversifying our customer base WEST ORANGE, N.J., Sept. 18, 2024 (GLOBE NEWSWIRE) — Bel Fuse Inc. (“Bel,” or, “the Company”) (Nasdaq:BELFA and Nasdaq:BELFB), today announced that it has entered into a definitive agreement to acquire a majority stake in Enercon Technologies, Ltd. (“Enercon”) from Fortissimo Capital based on an enterprise value of $400 million. Bel will acquire an 80% stake upfront for $320 million in cash (subject to customary adjustments), plus up to $10 million of potential earnout payments for the 2025-2026 period, with the intent to purchase the remaining 20% by early 2027 based on future EBITDA performance. Transaction highlights: Expands Bel’s exposure...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.